Novo Nordisk Launches New Insulin Injection Device in US - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novo Nordisk Launches New Insulin Injection Device in US
NovePen Echo is the first insulin injection device combining half-unit dosing and memory function


Novo Nordisk has launched a new insulin injection device, NovePen Echo, in the United States. According to the company, this is the first and only pen device available in the US with half-unit dosing and a memory function that records the dose and time passed since the last injection.

The half-unit dose increments mean that patients will be able to better adjust their insulin dose, which is particularly useful for children with diabetes. In addition, 12 fun removable skins are available for a customized look, including kid-friendly designs.

"We and believe this pen can help patients fine tune their dosing while offering added reassurance they are managing their diabetes appropriately," said George McAvoy, vice president of the NovoLog brand team at Novo Nordisk, in a press statement.

Children with Diabetes founder Jeff Hitchcock stated that it is important that new, innovative tools continue to be developed so that children and caregivers have options. “NovePen Echo, which features half-unit dosing from the start and memory function, is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home."

NovePen Echo is already available in Europe, Canada and Israel.

Source: Novo Nordisk

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here